Prodia Diagnostic Line Makes Indonesia Stock Exchange Debut

PT Prodia Diagnostic Line Tbk (PRDL) made its debut on the Indonesia Stock Exchange (IDX) on Thursday, July 9, 2026, becoming the sixth company to conduct an IPO this year.

Prodia offered 522.9 million new shares, equivalent to 30 percent of its fully paid-up capital post-IPO, at a final price of Rp120 per share. The company's stock price surged by 35 percent to Rp162 per share upon the opening of trading.

President Director of Prodia Diagnostic Line, Cristina Sandjaja, highlighted the IPO's success, noting the record-breaking 1.2 million retail orders and an oversubscription rate of 709 times. She attributed this strong investor reception to Prodia's attractive price-to-earnings ratio, which signaled the company's robust fundamentals.

Sandjaja acknowledged the challenges of proceeding with an IPO amid market pressures but expressed confidence in the IDX's enhanced screening process under new regulations, assuring investors of the quality of listed companies. Prodia's financial performance in 2025 showed significant growth, with revenues reaching Rp74.4 billion (a 27 percent increase year-on-year), net profit rising by 70.7 percent to Rp16.9 billion, and EBITDA increasing by 66.9 percent to Rp29.2 billion. The final share price was based on an 8.61 price-to-earnings ratio from the audited 2025 financial statements.

“

We see this as the first because Prodia's shares were offered at a very attractive price-to-earnings ratio, indicating the company's good fundamentals, which was appreciated by investors.